Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
IONS Stock Chart & Stats
$81.96
-$0.75(-2.14%)
At close: 4:00 PM EST
$81.96
-$0.75(-2.14%)
Day’s Range― - ―
52-Week Range$23.95 - $86.74
Previous CloseN/A
Volume126.35K
Average Volume (3M)2.16M
Market Cap
$13.54B
Enterprise Value$15.78B
Total Cash (Recent Filing)$2.68B
Total Debt (Recent Filing)$2.61B
Price to Earnings (P/E)―
Beta0.78
Next Earnings
May 06, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding165,192,020
10 Day Avg. Volume2,209,753
30 Day Avg. Volume2,162,412
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)25.88
Price to Sales (P/S)13.41
P/FCF Ratio-39.55
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue16.73
Enterprise Value/Gross Profit17.02
Enterprise Value/Ebitda3.48
Forecast
1Y Price Target
$95.86Price Target Upside16.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.78
Revenue Forecast (FY)$828.37M
Bulls Say, Bears Say
Bulls Say
Commercial Launch MomentumTryngolza's launch exceeded expectations with strong early sales driven by growing patient additions and volume, supporting confidence in the commercial sales force and uptake.
Pipeline And PartnershipsSeveral late-stage readouts and partnered program milestones, including major cardiovascular and genetic therapy trials, could unlock royalty streams and materially expand revenue diversification.
Regulatory ProgressPriority regulatory review for olezarsen or Tryngolza could accelerate approval timelines and bring projected sales forward relative to conservative guidance.
Bears Say
Competitive Pricing PressureEntry of a significantly discounted competing therapy could pressure market share and force deeper price concessions, reducing projected uptake for the company's product.
Conservative Guidance ImpactManagement's conservative revenue guidance that factors in higher gross-to-net discounts may understate near-term sales and prompted investor concern about short-term growth.
Pricing And Reimbursement RiskAnticipated payor negotiations and planned price adjustments for severe hypertriglyceridemia could lead to a materially lower net price and limit patient access, constraining revenue potential.
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $23.95 and its highest was $86.74 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $13.54B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is May 06, 2026 which is in 63 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Feb 25, 2026. The company reported -$1.41 earnings per share for the quarter, missing the consensus estimate of -$1.319 by -$0.091.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -0.83.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 165,192,020 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$1.41 in its last earnings report, missing expectations of -$1.319. Following the earnings report the stock price went down -5.29%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in IONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ionis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$95.86 (16.96% Upside)
$95.86 (16.96% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 745.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bullish
Bullish news 95%
Bearish news 5%
Bearish news 5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.85%
12-Months-Change
Fundamentals
Return on Equity
-70.72%
Trailing 12-Months
Asset Growth
17.32%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Company Deck
IONS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: multiple successful launches (TRYNGOLZA, DAWNZERA), landmark Phase III data (olezarsen, zilganersen), 34% revenue growth in 2025, expanding commercial infrastructure and robust partner progress underpin confident guidance and multibillion-dollar peak potential for key programs. Notable near-term risks and conservatism tempering outlook include guidance assuming a standard sNDA review (delaying broader sHTG sales), expected TRYNGOLZA revenue decline during transition and pricing negotiations, projected non-GAAP operating losses as commercial investments continue, cash use for debt repayment, and binary clinical/regulatory readouts (e.g., HORIZON) that carry execution risk. Overall, positive operational and clinical achievements substantially outweigh these manageable near-term financial and timing risks.View all IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$95.86
▲(16.96% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
Currently, No data available
---